Investor Overview
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first in class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases.
We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the VIB Gent, the University of Michigan, and more recently the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science.
Our most advanced in-house drug candidate is OATD-02, an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer that is expected to advance to Phase I clinical development in the second half of 2022.
In 2020 we signed an exclusive collaboration and license agreement with Galapagos for the global development and commercialization of OATD-01. OATD-01 (now GLPG4716) is a Phase II-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases such as sarcoidosis.
Our Business Model
- Our business model is based on successfully building a pipeline of small molecule drug candidates both internally and via selective in-licensing deals. We then plan to partner with global pharmaceutical and biotechnology companies for further clinical development and/or commercialization The preferred stage of development for out-licensing is early clinical Proof of Concept.
- Our partnerships with top global academic research institutes, combined with our exceptional capabilities in medicinal chemistry and translational science, have allowed the company to access the untapped, first/best-in-class novel biology targets – both mRNA and proteins – needed to generate a pipeline of first-in-class drug candidates.
- Our approach to drug discovery is based on bold target selection, both mRNA and proteins, traditionally undrugged by small molecules, with limited competition. Drug candidates developed using this approach have attractive commercial potential and will address disease areas with significant unmet medical needs.
- Our entrepreneurial/risk taking approach allows us to successfully work on challenging, high reward targets given our preferential access to the highly regarded and rapidly growing pool of Polish top life science talent.
Investor's calendar
| DATE | EVENT |
|---|---|
| March 31, 2022. | Publication of the Company's Annual Reports for the year 2021 (separate and consolidated) |
| April 29, 2022. | Publication of the Company’s quarterly report for I quarter of 2022 |
| September 30, 2022. | Publication of the Company’s semi-annual report for I half of 2022 |
| October 31, 2022. | Publication of the Company’s quarterly report for III quarter of 2022 |
Stock Quotes
Shareholding Structure
Shareholders
| THE NUMBER OF ACTIONS | NUMBER OF VOTES | SHARE IN THE SHARE CAPITAL | SHARE IN THE NUMBER OF VOTES | |
|---|---|---|---|---|
| BLACK FOREST SICAV - SIF societe anonyme * together with FTF Columbus Sp. z o. o., including: | 4 175 000 | 4 175 000 | 29,76% | 29,76% |
| BLACK FOREST SICAV - SIF societe anonyme * directly: | 4 135 000 | 4 135 000 | 29,47% | 29,47% |
| Indirectly through FTF Columbus Sp. z o. o | 40 000 | 40 000 | 0,29% | 0,29% |
| Marcin Szumowski together with Szumowski Investments sp. Z oo | 1 070 000 | 1 070 000 | 7,63% | 7,63% |
| Nationale-Nederlanden Universal Pension Society SA | 845 000 | 845 000 | 6,02% | 6,02% |
| The rest | 7 940 000 | 7 940 000 | 56,59% | 56,59% |
| TOTAL | 140 300 000 | 140 300 000 | 100,00% | 100,00% |
* Members of the Management Board, Supervisory Board and shareholders of the Company do not hold any shares of BLACK FOREST SICAV-SIF societe anonyme. The indirect owner of the shares is Michał Andrzej Sołowow. ** * 70,000 shares have not yet been admitted to trading.
Share in capital and number of votes
Financial Information
Financial Report
ON the WSE FROM
April 19, 2018
MARKET / QUOTATION SEGMENT
WSE / Parallel
SECTOR (WSE)
Biotechnology
INDEX AFFILIATION
WIG-Poland, WIG
WSE TICKER
POWER
ISIN
PLONCTH00011
NUMBER OF SHARES ISSUED
140,300
Contact
Contact with the media and individual investors
Michał Wierzchowski
CC GROUP
+48 531 613 067 +48 531 613 067michal.wierzchowski@ccgroup.pl
Contact with the media and individual investors
Katarzyna Mucha
CC GROUP
+48 697 613 712 +48 22 440 1 440katarzyna.mucha@ccgroup.pl